Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PfizerfiledCriticalPfizer
Publication of AR112757A1publicationCriticalpatent/AR112757A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Peptides Or Proteins
(AREA)
Abstract
La presente descripción proporciona: (a) polipéptidos de CEA inmunogénicos aislados; (b) moléculas de ácidos nucleicos aisladas que codifican (i) un polipéptido de CEA inmunogénico, (ii) un polipéptido de CEA inmunogénico y un polipéptido de MUC1 inmunogénico, (iii) un polipéptido de CEA inmunogénico y un polipéptido de TERT inmunogénico o (iv) un polipéptido de CEA inmunogénico, un polipéptido de MUC1 inmunogénico y un polipéptido de TERT inmunogénico; (c) composiciones que comprenden una molécula de ácidos nucleicos aislada; y (d) métodos relacionados con usos de los polipéptidos de CEA inmunogénicos, moléculas de ácidos nucleicos y composiciones.The present disclosure provides: (a) isolated immunogenic CEA polypeptides; (b) isolated nucleic acid molecules encoding (i) an immunogenic CEA polypeptide, (ii) an immunogenic CEA polypeptide and an immunogenic MUC1 polypeptide, (iii) an immunogenic CEA polypeptide and an immunogenic TERT polypeptide or ( iv) an immunogenic CEA polypeptide, an immunogenic MUC1 polypeptide and an immunogenic TERT polypeptide; (c) compositions comprising an isolated nucleic acid molecule; and (d) methods related to uses of immunogenic CEA polypeptides, nucleic acid molecules, and compositions.
oncolytic virus, virus expressing three heterologous genes, pharmaceutical composition, virus for use, manufacturing product, cancer treatment method, and virus use